Company Profile
Eurobio Scientific is a major player in the field of specialty in vitro diagnostics products, supplying into the diagnostics, research, transplantation, immunology, and infectious diseases, and industrial laboratories, including pharmaceutical and biotechnology companies. With numerous partnerships and a strong hospital presence, Eurobio Scientific has its own extensive distribution network and a portfolio of proprietary molecular biology products. The Eurobio Group has approximately 250 employees, including 40 scientists in R&D, three production units based in the Paris region, Germany and the USA, and subsidiaries in Surrey in the UK, Sissach in Switzerland, Bünde in Germany, and Utrecht in the Netherlands.
Approach to Healthcare
Eurobio Scientific is highly focused on the needs of its customers and in providing the highest quality products and service to improve the lives of patients through specialty diagnostics. It has developed a number of partnerships with Diagnostics manufacturers in order to supply customers with complete and innovative diagnostic solutions targeting niche markets.
Impact of Products/Services on Healthcare:
Our products have impacted across healthcare. From our Fungiline Fast solution providing rapid diagnostics for invasive aspergillosis and candidiasis, our RT-PCR solutions providing multi-thermocycler validated easily verifiable kits , our antiviral resistance NGS solutions from partners Vela Diagnostics, to to our point of care tests that provide rapid testing to emergency departments, pediatric departments and community based clinics. Collectively we can provide cost effective quicker diagnostic solutions
Innovation
Our Fungiline Fast lateral flow range brings a rapid diagnostic solution for invasive fungal infections. Our proprietary specialty Eurobioplex RT-PCR kits have just been launched on the UK market. This includes DermaScreen and DermaXtract for rapid nail dermatophyte diagnosis. Our R & D teams across the Eurobio Group are continuously collaborating and innovating to meet new patient and public health need.
Future Direction
We have recently partnered with USTAR Biotechnologies to bring point of care/near patient testing to our repertoire. We have additionally partnered with Diesse to bring both automation to Syphilis RPR and TPHA testing and an innovative infectious disease/automimmune/theraputic drug monitoring testing solution.